Pharvaris Stock Jumps 27% on Positive Hereditary Angioedema Trial
Pharvaris shares surged after the company announced a late-stage trial win for its hereditary angioedema drug, while Roivant reported positive phase 2 results for mosliciguat and Genflow Biosciences met its primary endpoint in a SLAB clinical trial.